Cutaneous Miscellaneous Podcast Episode 28:
Skin Care Startups: Launching Your Own Line
Featuring Anthony Rossi, MD | Release Date: July 24, 2024
In episode 28 of Cutaneous Miscellaneous, our host, Nicholas Brownstone, MD, gets to know Anthony Rossi, MD, dermatologist and Mohs micrographic surgeon at Memorial Sloan Kettering Cancer Center and founder of his own skin care line Dr. Rossi DERM MD®.
They start with a board review on Mohs surgery, covering critical indications and the appropriate use criteria from the American College of Mohs Surgery. They also discuss patient characteristics that favor Mohs surgery and when to consider antibiotic prophylaxis.
They then discuss starting a skin care line post-residency. Dr Rossi shares insights on creating a dermatologist-approved line, weighing the pros and cons of starting from scratch versus private labeling. He provides strategies for differentiating in a saturated market, observing trends, and developing a business model that focuses on repeat customers.
Tune in to the full episode for Dr Rossi ‘s valuable pearls and pitfalls for dermatologists interested in launching their own skin care lines and how to blend business acumen with dermatologic expertise!
Cutaneous Miscellaneous Boards Booster!
In this new feature, we’ll put your knowledge to the test with high-yield board review questions written by dermatology residents and fellows and sourced from key resources like Bolognia’s Dermatology, Andrews’ Dermatology, and Alikhan’s Review of Dermatology. These quiz questions will test your skills on the board review topic that’s discussed in each episode. Click here to begin.
Related CME
ATOPIC DERMATITIS, CME
PEDS24: Paving the Way for Non-Steroidal Topicals for Pediatric Patients With Atopic Dermatitis and Plaque Psoriasis: An Online Activity
30 min | Up to 0.5 CME credits
GENERALIZED PUSTULAR PSORIASIS (GPP), CME
FC24: Managing Generalized Pustular Psoriasis from Flare to Maintenance: Optimizing Patient Outcomes: An Online Activity
20 min | Up to 0.5 CME credits
ATOPIC DERMATITIS, CME
FC24: Is EASI 75 Good Enough or Can We Do Better? Elevating Efficacy and Long-Term Safety With JAK Inhibitors in Moderate-to-Severe Atopic Dermatitis: An Online Activity
45 min | Up to 0.75 CME credits